Login / Signup

Genomics-Driven Precision Medicine in Pediatric Solid Tumors.

Praewa SuthapotWararat ChiangjongParunya ChaiyawatPongsakorn ChoochuenDumnoensun PruksakornSurasak SangkhathatSuradej HongengUsanarat AnurathapanSomchai Chutipongtanate
Published in: Cancers (2023)
Over the past decades, several study programs have conducted genetic testing in cancer patients to identify potential genetic targets for the development of precision therapeutic strategies. These biomarker-driven trials have demonstrated improved clinical outcomes and progression-free survival rates in various types of cancers, especially for adult malignancies. However, similar progress in pediatric cancers has been slow due to their distinguished mutation profiles compared to adults and the low frequency of recurrent genomic alterations. Recently, increased efforts to develop precision medicine for childhood malignancies have led to the identification of genomic alterations and transcriptomic profiles of pediatric patients which presents promising opportunities to study rare and difficult-to-access neoplasms. This review summarizes the current state of known and potential genetic markers for pediatric solid tumors and provides perspectives on precise therapeutic strategies that warrant further investigations.
Keyphrases
  • free survival
  • copy number
  • childhood cancer
  • genome wide
  • public health
  • risk assessment